• Press Release

Mount Sinai Health System Launches DigniCap Scalp Cooling System for Women with Breast Cancer

  • New York, NY
  • (November 30, 2016)

The Mount Sinai Health System (MSHS) announced the launch of the DigniCap® scalp cooling system, which was recently cleared by the U.S. Food and Drug Administration (FDA) to reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, in three of its cancer center locations. Mount Sinai is also the first and only health system in New York to currently offer breast cancer patients the Dignicap, which is now available at the Dubin Breast Center of The Tisch Cancer Institute, Mount Sinai Downtown-Chelsea, and Mount Sinai West. In the FDA clinical trials completed in the United States, 7 out of 10 patients with early-stage breast cancer kept at least 50 percent of their hair.   

“We are extremely excited to be able to offer patients the Dignicap scalp cooling system during chemotherapy, which allows them to retain normalcy and privacy in their lives,” said Paula Klein, MD, Associate Professor of Oncology and Hematology at the Icahn School of Medicine at Mount Sinai, who studied the Dignicap system as part of a multi-center clinical trial which eventually led to FDA clearance in December 2015. “Losing hair is one of the more distressing side effects of chemotherapy, and this is a game changer for so many patients.”

The DigniCap scalp cooling system, made by the Swedish company Dignitana AB, with U.S. headquarters in Dallas, Texas, features a patented tight-fitting silicone cooling cap that is placed directly on the head and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch-screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intrafollicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.

“Time and time again, I have heard so many of my female patients with breast cancer tell me that hair loss was the worst part of their chemotherapy,” said Charles Shapiro, MD, Director of Translational Breast Cancer and Research, and Director of Cancer Survivorship at The Tisch Cancer Institute. “But now there is a treatment to mitigate this side effect and help to improve a patient’s experience during a very difficult time in their life.”
               
"Mount Sinai was an important partner for Dignitana as we clinically tested the DigniCap system to ensure safety and efficacy," said Bill Cronin, CEO of Dignitana, Inc. "To be able now to offer women throughout the entire Mount Sinai system an alternative to chemotherapy-induced hair loss is a major step forward in our vision to make what for many is an emotionally traumatic side effect, a thing of the past."


About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The System includes approximately 6,600 primary and specialty care physicians; 10 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 13 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke's and Mount Sinai West are ranked regionally.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.